Prognostic significance of WT1 expression at diagnosis and end of induction in Egyptian adult acute myeloid leukemia patients

Hematology

Volumn 18, Issue 2, 2013, Pages 69-73

  Mossallam, Ghada I ^a   Abdel Hamid, Thoraya M ^b   Mahmoud, Hossam K ^b  

^a NATIONAL CANCER INSTITUTE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Acute myeloid leukemia; Minimal residual disease; Prognosis; Wilms' tumor gene

Indexed keywords

CYTARABINE; DAUNORUBICIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EGYPT; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WILM TUMOR GENE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; EGYPT; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WT1 PROTEINS; YOUNG ADULT;

EID: 84875697367     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/1607845412Y.0000000048     Document Type: Article

References (30)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-62.
2. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9(14):1-17.
3. Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40(5):377-87. Epub 2010 Apr 15.
4. Inoue K, Sugiyama H, Ogawa, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
5. Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br J Haematol. 2004;125(5):590-600.
6. Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E, Fava M, et al. Early prediction of treatment outcome in acute myeloid leukaemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica 2008;93:921-4.
7. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997;90(3):1217-25.
8. Barragan E, Cervera J, Bolufer P, Ballester S, Martín G, Fernández P, et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 2004;89(8):926-33.
9. Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997; 11(5):639-43.
10. Gaiger A, Schmid D, Heinze G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998; 12(12):1886-94.
11. Busse A, Gökbuget N, Siehl JM, Hoelzer D, Schwartz S, Rietz A, et al. Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol. 2009;88(12):1199-205.
12. Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma 2010;51(10):1855-61.
13. Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia. Haematologica 2004;89(5):528-40.
14. Buccisano F, Maurillo L, Del Principe MI, Del Poeta G, Sconocchia G, Lo-Coco F, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119(2):332-41.
15. Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Ceresoli E, Lo Coco F, et al. Monitoring of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol. 2009; 21(6):582-8.
16. Garg M, Moore H, Tobal K, Liu Yin JA. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol. 2003;123(1):49-59.
17. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005;19(8):1416-23.
18. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol. 2008;141(6):782-91.
19. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31): 5195-201.
20. Nowakowska-Kopera A, Sacha T, Florek I, Zawada M, Czekalska S, Skotnicki AB. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk Lymphoma 2009;50(8):1326-32.
21. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002; 16(10):2115-21.
22. Trka J, Kalinova M, Hrusak O, Zuna J, Krejci O, Madzo J, et al. Real time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002;16:1381-9.
23. Noronha SA, Farrar JE, Alonzo TA, Gerbing RB, Lacayo NJ, Dahl GV, et al. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009;53(6):1136-9.
24. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24(10):1507-15.
25. Yanada M, Terakura S, Yokozawa T, Yamamoto K, Kiyoi H, Emi N, et al. Multiplex real-time RT-PCR for prospective evaluation of WT1 and fusion gene transcripts in newly diagnosed de novo acute myeloid leukemia. Leuk Lymphoma 2004;45(9): 1803-8.
26. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996;88:2267-78.
27. Gray JX, McMillen L, Mollee P, Paul S, Lane S, Bird R, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leuk Res. 2012;36(4):453-8.
28. Ochsenreither S, Fusi A, Busse A, Bauer S, Scheibenbogen C, Stather D, et al. Wilms Tumor Protein 1′′ (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow. J Immunother. 2011;34(1):85-91.
29. Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms' Tumor Protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012; 17(2):250-9.
30. Giacomo G, Francesco M, Vanessa P, Giovanni L, Sara B, Alberto B, et al. Early reduction of WT1 transcripts during induction chemotherapy predicts for longer disease free and overall survival in acute myeloid leukemia. Haematologica 2010;95(5):833-6.